Ascelia Pharma AB AI Stock Analysis
Want to see SE:ACE full AI Analyst Report?
Ascelia Pharma AB (ACE) AI Stock Analysis
Ascelia Pharma AB
(Nasdaq OMX AB:ACE)
The score is driven primarily by very weak financial fundamentals: zero revenue, a TTM net loss of about SEK 54.7 million, and roughly SEK 61.7 million of annual operating cash burn against an equity base of only about SEK 80 million, pointing to a near-term funding need and likely shareholder dilution. Technicals compound the concern, with the price trading well below all key moving averages — notably the 200-day at 1.865 versus a last close of 0.533 — and negative MACD confirming a prolonged downtrend. Valuation provides no cushion given negative earnings and no dividend. Mitigating factors are a nearly debt-free balance sheet, equity funding close to 88% of assets, and a meaningfully reduced cost base, with losses and burn roughly halved from 2022–2023 peaks. The investment case rests almost entirely on future clinical and partnering milestones rather than current financial performance.
Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 76.65M
- Dividend Yield
- ―
- Average Volume (3M)
- 955.66K
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 0.67
- Revenue Growth
- ―
- EPS Growth
- 50.59%
- Country
- Sweden
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ascelia Pharma AB Business Overview & Revenue Model
Company Description
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trial...
How the Company Makes Money
Ascelia Pharma’s business model is centered on successfully developing, obtaining regulatory approval for, and then commercializing its product candidates, with future revenues expected to come primarily from product sales of its lead candidate, Orvi...
Ascelia Pharma AB Financial Statement Overview
Summary
Ascelia Pharma is a pre-revenue clinical-stage biotech with no sales in any reported period and persistent losses (TTM operating loss of roughly SEK 55.5 million and net loss of about SEK 54.7 million). Operations consumed about SEK 61.7 million of cash over the TTM period, with free cash flow essentially matching the net loss, implying limited runway against an equity base of roughly SEK 80 million and a high likelihood of dilutive financing. The positives are genuine but secondary: losses and cash burn have roughly halved from 2022–2023 levels after pipeline reprioritization, debt is negligible at about SEK 0.3 million, and equity funds close to 88% of assets. However, the capital base has eroded sharply from about SEK 308 million in 2021, and return on equity remains deeply negative at around -62%, leaving financial quality weak on an absolute basis.
Income Statement
11Very NegativeBalance Sheet
45NeutralCash Flow
13Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -888.00K | -938.00K | -1.05M | -3.89M | -8.72M |
| EBITDA | -55.60M | -73.24M | -66.83M | -108.56M | -132.06M | -128.42M |
| Net Income | -54.75M | -76.25M | -80.03M | -109.29M | -131.22M | -125.90M |
Balance Sheet | ||||||
| Total Assets | 90.27M | 111.94M | 140.92M | 87.07M | 218.57M | 333.49M |
| Cash, Cash Equivalents and Short-Term Investments | 27.80M | 49.86M | 75.26M | 21.86M | 149.56M | 261.60M |
| Total Debt | 285.00K | 1.04M | 25.40M | 1.06M | 484.00K | 1.66M |
| Total Liabilities | 10.58M | 12.47M | 61.98M | 12.74M | 37.71M | 25.66M |
| Stockholders Equity | 79.69M | 99.47M | 78.94M | 74.33M | 180.86M | 307.83M |
Cash Flow | ||||||
| Free Cash Flow | -61.66M | -72.31M | -62.84M | -126.79M | -125.33M | -116.60M |
| Operating Cash Flow | -61.66M | -72.25M | -62.84M | -126.79M | -125.26M | -116.56M |
| Investing Cash Flow | 0 | -57.00K | 0 | 46.00K | -65.00K | -38.00K |
| Financing Cash Flow | 17.29M | 48.21M | 115.19M | -936.00K | -1,100 | 184.87M |
Ascelia Pharma AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Neutral. The current price of 0.57 is above the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.62, and below the 200-day MA of 1.82, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 30.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACE.
Ascelia Pharma AB Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:BINV49Neutral
SE:IMMU48Neutral
SE:ONCO44Neutral
SE:ONCOZ39Underperform
SE:ACE29Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 369.63M | 1.93 | 63.09% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 193.46M | -0.40 | -128.54% | ― | -83.67% | -50.29% | |
| 48Neutral | SEK 240.41M | -2.12 | -19.14% | ― | ― | 13.06% | |
| 44Neutral | SEK 747.11M | -2.75 | ― | ― | 65.37% | 43.28% | |
| 39Underperform | SEK 84.18M | -1.30 | -970.69% | ― | 115.26% | -230.43% | |
| 29Underperform | SEK 76.65M | -1.33 | -62.23% | ― | ― | 50.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ACE | Ascelia Pharma AB | 0.57 | -2.32 | -80.17% | |
| SE:BINV | BioInvent International AB | 2.94 | -27.96 | -90.49% | |
| SE:ONCO | Oncopeptides AB | 1.73 | -3.24 | -65.16% | |
| SE:ONCOZ | OncoZenge AB | 3.05 | -1.65 | -35.06% | |
| SE:IMMU | Immunicum AB | 3.79 | -1.81 | -32.32% | |
| SE:CANTA | Cantargia AB | 1.31 | -1.92 | -59.41% |
Ascelia Pharma AB Corporate Events
Ascelia Pharma Resolves to Convert Series C Shares for Incentive Program
Ascelia Pharma’s board resolved on 9 November 2026 to convert 79,142 series C shares into ordinary shares and allot them to participants in its LTI 2023 performance-based share saving program. Eight participants were allotted shares, including 34,410...
FDA Seeks Additional Evidence for Ascelia’s Orviglance
In July, the U.S. Food and Drug Administration issued a Complete Response Letter for Orviglance, citing issues with clinical data and product documentation. Official minutes from a September Type A meeting confirmed that additional clinical evidence...
Ascelia Pharma Charts New Path for Orviglance After FDA Meeting
Ascelia Pharma has received official minutes from its Type A meeting with the U.S. FDA regarding the Complete Response Letter for the Orviglance New Drug Application, confirming that the agency still wants additional clinical evidence, ideally from a...
Ascelia Pharma’s Orviglance Study Published in Leading MRI Journal
Ascelia Pharma AB, a Malmö-based biotech company listed on Nasdaq Stockholm and focused on orphan oncology treatments, is developing two key drug candidates: Orviglance, a manganese-based MRI contrast agent for liver imaging, and Oncoral. The company...
Ascelia Pharma Holds FDA Type A Meeting on Orviglance NDA
Ascelia Pharma has completed a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter issued for the Orviglance New Drug Application. The meeting was aimed at clarifying the steps required to secure U.S. reg...
Ascelia Pharma Tightens Costs After FDA Setback on Orviglance
Ascelia Pharma reported that its primary focus in the first half of 2026 has been advancing Orviglance through the U.S. regulatory process and preparing for potential commercial partnering once approval is secured. The company completed a SEK 20 mill...
Ascelia Pharma Secures FDA Type A Meeting on Orviglance NDA
Ascelia Pharma said the U.S. Food and Drug Administration has scheduled a Type A meeting on September 9, 2026 to discuss the Complete Response Letter issued for the New Drug Application of Orviglance. The meeting will allow the company and the regula...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
